



Contents lists available at ScienceDirect

International Journal of Hygiene and Environmental Health

journal homepage: www.elsevier.com/locate/ijheh

In vitro cytotoxic effects of secondary metabolites of DEHP and its alternative plasticizers DINCH and DINP on a L929 cell line

Teuta Eljezi^{a,1}, Pierre Pinta^{b,1}, Fabien Nativel^b, Damien Richard^c, Jérémy Pinguet^c, Olivier Roy^d, Valérie Sautou^a, Gaël Grimandi^b, Emmanuel Moreau^{a,*}

^a Université Clermont- Auvergne, Imagerie Moléculaire et Stratégies Théranostiques, Inserm U1240, Centre Jean Perrin, BP 184, F-63005, Clermont-Ferrand, France

^b Inserm, UMR 1229, Regenerative Medicine and Skeleton (RMeS), Université de Nantes, ONIRIS, 44042, Nantes, France

^c Service de Pharmacologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France

^d Université Clermont Auvergne, CNRS, SIGMA Clermont, ICCF, F-63000, Clermont-Ferrand, France

ARTICLE INFO

Keywords:

DINCH
DINP
Metabolite synthesis
Cytotoxicity
DEHP-Alternative plasticizers

ABSTRACT

Background: Phthalic acid esters are widely used to improve the plasticity of PVC in medical devices (MD). The most famous plasticizer is **DEHP**, whose use in medical devices has been contested by the European authorities since 2008. Several alternative plasticizers are being considered to replace **DEHP**, such as **DEHT**, **TOTM**, **DINP** or **DINCH**, but they are also released from the PVC throughout their life cycle and are metabolized in the same way as **DEHP**.

Objectives: Our study focuses on the *in vitro* cytotoxicity of two alternative plasticizers (**DINCH** and **DINP**) contained in certain medical devices. They are likely to migrate and be transformed *in vivo* into the primary and secondary metabolites by a metabolism similar to that of **DEHP**. This preliminary study is the first to assess the *in vitro* cytotoxicity of oxidized metabolites of **DINCH** and **DINP** based on the EN ISO 10-993-5 standards documents.

Methods: We have studied the complete multi-step organic synthesis of secondary metabolites of **DINP** and **DINCH** and have performed cytotoxicity tests on L929 murine cells according to the EN ISO 10993-5 standard design for the biocompatibility of a MD. The tested concentrations of obtained metabolites (0.01, 0.05 and 0.1 mg/mL) covered the range likely to be found for **DEHP** (total metabolism) in biological fluids coming into direct contact with the MD. The concentrations tested in our study were chosen based on a complete transformation of the plasticizers released after direct contact between a MD and the patient's blood.

Results: Only **7-oxo-MMeOCH** is cytotoxic at the highest concentration (0.1 mg/mL) after 7 days of exposure, just like **5-oxo-MEHP** for the same concentration. By contrast, **7-OH-MMeOP**, **7-cx-MMeOP**, **7-oxo-MMeOP**, **7-OH-MMeOCH** and **7-cx-MMeOCH** were not found to be cytotoxic.

Conclusion: The known concentrations of these secondary metabolites in urinary samples are in the µg/L range, i.e. about 100–1000 times lower than the concentrations tested in this study. Cytotoxicity is known to be dose-dependent but it is not always the case for endocrine perturbations and the secondary metabolites could induce endocrine perturbations at very low doses.

Abbreviations: ARMED[®], Assessment and Risk Management of Medical Devices in Plasticized Polyvinylchloride; **DEHP**, diethylhexyl phthalate; **DINCH**, diisononyl cyclohexane-1,2-dicarboxylate; **DINP**, diisononylphthalate; **MEHP**, monoethylhexyl phthalate; **MMeOP**, mono(4-methyloctyl)phthalate; **MMeOCH**, mono(4-methyloctyl) cyclohexane-1,2-dicarboxylate; **MINCH**, monoisononyl cyclohexane-1,2-dicarboxylate; **MINP**, monoisononylphthalate; **7-oxo-MMeOCH**, mono(4-methyl-7-oxooctyl) cyclohexane-1,2-dicarboxylate; **7-OH-MMeOCH**, mono(7-hydroxy-4-methyl-octyl) cyclohexane-1,2-dicarboxylate; **7-cx-MMeOCH**, mono(7-carboxy-4-methyl-octyl) cyclohexane-1,2-dicarboxylate; **7-oxo-MMeOP**, mono(4-methyl-7-oxooctyl)phthalate; **7-OH-MMeOP**, mono(7-hydroxy-4-methyloctyl)phthalate; **7-cx-MMeOP**, mono(7-carboxy-4-methyloctyl)phthalate; **SCENIHR**, Scientific Committee on Emerging and Newly-Identified Health Risks

* Corresponding author. Université Clermont- Auvergne, Imagerie Moléculaire et Stratégies Théranostiques, BP 184, F-63005, Clermont-Ferrand, France.

E-mail address: emmanuel.moreau@uca.fr (E. Moreau).

¹ Both authors contributed equally.

<https://doi.org/10.1016/j.ijheh.2019.03.005>

Received 25 October 2018; Received in revised form 9 March 2019; Accepted 12 March 2019

1438-4639/ © 2019 Elsevier GmbH. All rights reserved.

1. Introduction

Some phthalate esters present a general concern for public health due to their wide use in the manufacturing of polymeric materials and various consumer products. Some phthalate esters can be classified into two categories according to the number of carbons in the ester chain. On the one hand, there are those with a low molecular weight (number of carbon inferior to 6) which are used as industrial solvents, lubricants, and as components in personal-care products. On the other hand, those with a high molecular weight are commonly used as plasticizers, conferring better flexibility and durability to everyday polyvinyl chloride (PVC) consumer products, such as flooring, food packaging, clothing, children's toys and medical devices (Hauser and Calafat, 2005). These PVC plasticizers can be released from the polymers by volatilization into the air, abrasion of the polymer, leaching into liquids and direct diffusion from the polymer into dust on the polymer surface, resulting in subsequent human exposure which might cause adverse health effects (Giovanoulis G et al., 2018; Zhang, S. et al., 2016; Engel, A. et al., 2017, 2018). With regard to their presence in PVC medical devices, the most famous plasticizers is **DEHP**, whose use has been contested by the European authorities (SCENHIR, 2008, 2016). The toxic potential of **DEHP** is largely due to the metabolic transformation into more toxic metabolites by hydrolysis (**MEHP**) and subsequent oxidation reactions (**5-OH-MEHP**, **5-oxo-MEHP**, **5-cx-MEHP**) (Fig. 1A). Numerous studies have been carried out on **DEHP**, leading to its classification as carcinogenic, mutagenic or toxic for reproduction (CMR1B) because of its toxic effects on reproduction and fertility in rodents. Its use is now highly controlled in medical devices. The European regulation 2017/745 recommends not to exceed a rate of 0.1% in mass fraction in each medical device (Regulation (EU) 2017/745). Two alternative plasticizers (diisononyl phthalate (**DINP**) and 1,2-cyclohexane dicarboxylic acid (**DINCH**)) have been considered by manufacturers as a replacement for **DEHP** in many PVC products, such as medical devices and food packaging, but are limited in toys with concentrations inferior to 0.1% by weight of the plasticized material (European Chemical Agency, 2013; SCENHIR, 2016), due to their physicochemical properties suggesting a lower migration and more favorable toxicological profile

(Fromme et al., 2016; Bhat et al., 2014) than **DEHP**. **DINP** and **DINCH** respectively constitute a complex commercial mixture composed mainly of isomers of phthalate or dialkyl cyclohexanoate with 9 carbon chains. **DINCH** (Hexamoll[®]) is manufactured by catalytic hydrogenation of the aromatic ring of diisononyl phthalate (Palatinal[®] N) into the cyclohexane ring existing predominantly in the most stable chair configuration, allowing cis- and trans-configuration. The typical commercial products consist of 90% cis- and 10% trans-isomers. In both molecules, the 4-methyl isomer forms a fraction that represents less than 50% of the total C9 alcohols (Schütze et al., 2017). Like **DEHP**, they are not covalently bonded to the PVC to which they are mixed. As a result, they are released from the products throughout their life cycle (Bernard et al., 2015; Jeon et al., 2016). Because they are a mixture of isomers, their metabolites are also isomeric mixtures (Silva et al., 2013). Both are initially hydrolyzed in rodents and humans into their monoester (**MINP** or **MINCH**), followed by oxidative processes into several metabolites including mono-hydroxy, mono-oxo and mono-carboxymetabolites (Silva et al., 2007a, 2007b; Koch et al., 2007, Koch and Angerer, 2007, 2013) (Fig. 1B).

Some biomonitoring studies carried out in humans have made it possible to demonstrate the presence of **DINCH** and **DINP** metabolites in biological media such as urine, blood and nails (Giovanoulis et al., 2016, 2018, Correia-Sa et al., 2017, Schütze et al., 2012, 2017, Zeman et al., 2013; Koch et al., 2017, Johns et al., 2015). However, despite the animal toxicology data and the *in vitro* toxicity of the plasticizers, there is almost no information on the *in-vitro* toxicity of the oxidized metabolites of **DINP** and **DINCH** from medical devices except the urinary metabolites of **DINCH**, which seem to have an impact on the activities of the human nuclear receptors ER α , ER β , AR, PPAR α and PPAR γ . However, the *in vitro* data does not support the notion that **DINCH** or any of the investigated metabolites may exert considerable endocrine effects *in vivo* at relevant human exposure levels. (Engel et al., 2017, 2018). In a previous study we investigated the cytotoxicity of **DEHP**, **DINCH**, **DINP** and their corresponding primary unconjugated metabolites (**MEHP**, **MINCH**, **MMeOCH**, **MINP**, respectively), and showed that the primary metabolites are more cytotoxic than their corresponding plasticizer at concentrations between 0.01 and 0.1 mg/mL. Only




Fig. 1. Primary and secondary metabolites of **DEHP**, **DINCH**, **DINP**, **MeDINCH** and **MeDINP**.

MMeOP, the primary metabolite of **DINP**, is not cytotoxic at these concentrations (Eljezi et al., 2017). Taking into account that **DINP** and **DINCH** are metabolized in the same way as **DEHP**, secondary metabolites are also found in the urine (7-oxo-MMeOCH, 7-OH-MMeOCH, 7-cx-MMeOCH, 7-oxo-MMeOP, 7-OH-MMeOP and 7-cx-MMeOP) in a glucuroconjugated form or not. According to the data in the literature, it appears that 26% of **cx-MINCH** are excreted in its unconjugated form in urine (Koch et al., 2013). These results are similar to the previous work concerning **DEHP** and **DINP** (Silva et al., 2013). In continuation of our work on alternative plasticizers to **DEHP**, we therefore undertook the total synthesis of the secondary metabolites of **DINP** and **DINCH** in order to be able to carry out a first cytotoxicity study on the NCTC clone 929 in accordance with the EN ISO 10-993-5 standards documents.

2. Materials and methods

2.1. Chemicals, biochemicals and reagents

Unless otherwise mentioned, all manipulations were performed under an argon atmosphere. All reagents were purchased from the following commercial suppliers: Sigma-Aldrich, Acros Organics, Carlo Erba, TCI Europa, and Alpha Aesar. Anhydrous DMF and anhydrous triethylamine were purchased from Acros Organics. THF was distilled over benzophenone and sodium. Dichloromethane was distilled over calcium hydride. Nuclear magnetic resonance (NMR) spectra were acquired on a Bruker AC-200 or AC-400 instrument operating at 200 MHz and 50 MHz or 400 MHz and 100 MHz for ¹H NMR and ¹³C NMR, respectively. All ¹H NMR and ¹³C NMR spectral peaks are reported in δ units, parts per million (ppm), and the coupling constants are indicated in hertz (Hz). The following abbreviations are used for spin multiplicity: s = singlet, d = doublet, t = triplet, q = quadruplet, m = multiplet, and br = broad. The chromatographic system consisted of an HTC PAL autosampler, and a Transcend TLX-1 HTLC System (ThermoFisher Scientific, San Jose, United States). The HRMS analysis was performed using a Thermo Exactive benchtop Orbitrap[®] instrument. TLC was performed on pre-coated silica gel sheets (POLYGRAM[®] 60F254 plates) and visualized under UV light (254 nm). Revelators used were KMnO₄ (1.5 g KMnO₄, 10 g K₂CO₃, and 1.25 mL 10% NaOH in 200 mL water) and ninhydrin (1.5 g ninhydrin in 100 mL of n-butanol with 3 mL AcOH). Column chromatography was performed using a silica gel normal phase (35–70 μ m). A HPLC Prominence-i LC-2030 CSHIMA-DZU with Kinetex 5 μ m EVO C18 (Phenomenex) column with pore diameter (A) 82–102, particle size (μ m) 4.5–4.8, and column dimensions of 50 $\times$ 4.6 mm was used to purify secondary metabolites. Uncorrected melting points (Mp) were recorded on an Electrothermal IA9300 apparatus. Infrared spectra (IR) were recorded on a Bruker FT Vector 22. The 5-oxo-MEHP, 5-OH-MEHP and 5-cx-MEHP compounds were synthesized using the procedure described by Nüti et al. (Nüti et al., 2005).

Dimethylsulfoxide DMSO (ref: D8418 CAS: 67-68-5), Mouse fibroblasts L929 (ref: 85011425 lot: 10L019), MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, ref: M2128) were also purchased from Sigma Aldrich. Dulbecco's modified Eagle Medium (DMEM) (fetal calf serum (SVF), phosphate saline buffer (PBS), penicillin (P), streptomycin (S), and actinomycin D) were purchased from Life technologies SAS, France. For more details, see supporting information.

2.2. Methods for the synthesis of the secondary metabolites 7-oxo-MMeOCH, 7-OH-MMeOCH, 7-cx-MMeOCH, 7-oxo-MMeOP, 7-OH-MMeOP and 7-cx-MMeOP

Metabolites **7-oxo-MMeOCH**, **7-OH-MMeOCH**, **7-cx-MMeOCH**, **7-oxo-MMeOP**, **7-OH-MMeOP** and **7-cx-MMeOP** were synthesized from the appropriate anhydrides (hexahydroisobenzofuran-1,3-dione or phthalic anhydride) and 7-(benzyloxy)-4-methylheptan-1-ol previously

synthesized and characterized (¹H, ¹³C NMR and HRMS) by our lab (Eljezi et al., 2017). The benzyl group at ω -position was then removed under hydrogen atmosphere and the resulting alcohol was oxidized into an aldehyde compound which was converted into vinyl compounds **6** or **18**. From the appropriate vinyl compound (**6** or **18**), **7-oxo-MMeOCH** or **7-oxo-MMeOP** could be obtained by oxidation in a mixture of PdCl₂ and parabenzoquinone. These were directly converted into **7-OH-MMeOCH** or **7-OH-MMeOP** by a regioselective reduction in the presence of NaBH₄. Concerning **7-cx-MMeOCH** or **7-cx-MMeOP**, they were obtained from vinyl derivatives **6** or **18** by hydroboration followed by an oxidation in the presence of Jones reagent. The purity of all synthesized metabolites was over 95% (HPLC/MS). All experimental details are described in the supporting material.

2.3. Biocompatibility assays

For the solubilization of the plasticizers, cell cultures, viability assays for the synthesized metabolites and statistical analysis, we used the same procedures previously described by us (Eljezi et al., 2017). For more details, see supporting information.

3. Results


3.1. Synthesis of MeDINCH and MeDINP secondary metabolites

The three metabolites of the **MeDINCH** plasticizer, i.e. **7-oxo-MMeOCH**, **7-OH-MMeOCH** and **7-cx-MMeOCH**, were synthesized from monoprotected alcohol **1** (Eljezi et al., 2017) and hexahydroisobenzofuran-1,3-dione (Scheme 1). Acid compound **2** was esterified, followed by a catalytic hydrogenation to produce compound **4**. The hydroxy group at ω -position of the alkyl chain was oxidized into an aldehyde. Compound **5** reacted with isopropyltriphenylphosphonium iodide (Wittig reaction) to obtain vinyl derivative **6**. According to the procedure previously described (Nüti et al., 2005), this vinyl function produced a ketone function at position C-7 of the alkyl chain (compound **7**) which was converted into **7-oxo-MMeOCH** after a soft saponification. Compound **7** was also reduced in the presence of NaBH₄ followed by a treatment with lithium hydroxide monohydrate to give **7-OH-MMeOCH**. Finally, the third secondary metabolite, **7-cx-MMeOCH**, was obtained from compound **6** after a hydroboration of the vinyl function, followed by an oxidation of the primary alcohol function with Jones reagent and a soft saponification. All of these syntheses are depicted in Scheme 1.

The secondary metabolites **7-oxo-MMeOP**, **7-OH-MMeOP** and **7-cx-MMeOP** were synthesized using a similar strategy developed for secondary metabolites of **MeDINCH** (Scheme 2). Briefly, vinylic precursor **18** was obtained by condensation of the monoprotected alcohol **1**, and anhydride phthalic, followed by an esterification, deprotection of the ω -hydroxy group at C-7 position, then its oxidation and a Wittig reaction. Finally, this vinyl function enabled **7-oxo-MMeOP** to be obtained in two steps (Wacker oxidation and a soft saponification), then **7-OH-MMeOP** by a reduction in presence of NaBH₄. Compound **7-cx-MMeOP** was obtained after a hydroboration, followed by an oxidation with Jones reagent.


3.2. Viability of cells when exposed to the secondary metabolites of plasticizers

Fig. 2 shows the results of viability tests, at day 7 (D7), performed on L929 cells cultured in the presence of the three concentrations of plasticizers after 7 days of contact. Compounds **5-cx-MEHP**, **5-OH-MEHP**, **7-cx-MMeOCH**, **7-OH-MMeOCH**, **7-cx-MMeOP**, **7-OH-MMeOP**, **7-oxo-MMeOP** were not toxic to the cells at concentrations of 0.01, 0.05, and 0.1 mg/mL compared with the control containing DMSO at the same concentrations. A decrease in cell viability was observed for **5-oxo-MEHP** and **7-oxo-MMeOCH** from the concentration of



Conditions and reagents: i) 1,2-cyclohexane dicarboxylic anhydride, pyridine, 125°C; ii) EtOH, H_2SO_4 , Δ ; iii) H_2 , Pd/C (1 bar); iv) PCC, dichloromethane, rt; v) isopropyltriphenylphosphonium iodide, n-BuLi, THF, -78°C to rt; vi) PdCl_2 , p-benzoquinone, DMF/ H_2O (7/1; v/v), rt; vii) LiOH (1M), THF/methanol (3/1; v/v), rt; viii) NaBH_4 , ethanol, rt; ix) B_2H_6 (1M), THF, rt; x) Jones reagent, rt;

Scheme 1. Synthesis of secondary metabolites 7-oxo-MMeOCH, 7-OH-MMeOCH and 7-cx-MMeOCH.



Conditions and reagents: i) a) phthalic anhydride, pyridine, 125°C; b) EtOH, H_2SO_4 , Δ ; ii) H_2 , Pd/C (1 bar); iii) PCC, dichloromethane, rt; iv) isopropyltriphenylphosphonium iodide, n-BuLi, THF, -78°C to rt; v) PdCl_2 , p-benzoquinone, DMF/ H_2O (7/1; v/v), rt; vi) LiOH (1M), THF/methanol (3/1; v/v), rt; vii) NaBH_4 , ethanol, rt; viii) B_2H_6 (1M), THF, rt; ix) Jones reagent, rt;

Scheme 2. Synthesis of secondary metabolites 7-oxo-MMeOP, 7-OH-MMeOP and 7-cx-MMeOP.




Fig. 2. Cytotoxicity tests of secondary metabolites at 0.01 mg/mL, 0.05 mg/mL and 0.1 mg/mL, on day 7. Outcomes of the cell viability analysis using a MTT assay. L929 cells were seeded at 10^4 cells/well and cultured for 7 days in three conditions: control (complete medium), control DMSO (complete medium supplemented with 0.1%, 0.5% and 1% DMSO) and test (working solutions of the plasticizer in complete medium at 0.01 mg/mL, 0.05 mg/mL and 0.1 mg/mL). MTT assays and quantification of the viability percentage were carried out every day. * $p < 0.05$ DMSO control vs Test.

0.1 mg/mL. A significant decrease in viability of over 50% was observed for 5-oxo-MEHP.

4. Discussion

For several years, our research program has focused on DEHP and some of the corresponding alternatives in medical devices. DINCH and DNP are two plasticizers commonly used as alternatives to DEHP in PVC medical devices. DINCH is used in parenteral and enteral nutrition tubings as well as in hemodialysis lines (Strømmen et al., 2016). DNP is added to some PVC infusions tubings or blood transfusion sets (Frederiksen et al., 2014; Bernard et al., 2015; Bourdeaux et al., 2016). Like DEHP, these plasticizers are also known to migrate from medical devices and to enter into contact with the patient's body where they are metabolized into primary and secondary forms (Bernard et al., 2015). Based on data obtained from ICU studies carried out in recent years (Frederiksen et al., 2014; Huygh et al., 2015; Strømmen et al., 2016), it seems that these metabolites are less present in the urine than those of DEHP. Although these metabolites are mainly eliminated in their conjugated form in the urine, about 26% of the acid form is in its free form (5cx-MINCH) (Koch et al., 2013). Similar data have been published for DEHP and DNP (Silva et al., 2013). The cytotoxicity of their respective primary metabolites (MINCH, MeMINCH, MINP and MeMINP) has also been evaluated (Eljezi et al., 2017) but the cytotoxicity of the secondary metabolites of DINCH and DNP have not currently been studied. We thus synthesized these secondary metabolites (7-oxo-MMeOCH, 7-OH-MMeOCH, 7-cx-MMeOCH, 7-oxo-MMeOP, 7-OH-MMeOP and 7-cx-MMeOP) in sufficient quantities to complete preliminary cytotoxicity test. Based on the urinary concentrations found for these secondary metabolites (conjugates or not), the concentrations of the secondary metabolites of DEHP are much higher than those of DNP and DINCH (0.3–5 $\mu\text{g/mL}$ for ΣDEHPm versus 0.008–0.1 $\mu\text{g/mL}$ for ΣDINPm and ΣDINCHm) (Frederiksen et al., 2014; Huygh et al., 2015; Strømmen et al., 2016). We therefore evaluated the cytotoxicity of the secondary metabolites of DNP and DINCH over a larger concentration range (0.01–1 mg/mL), which is a very pessimistic scenario, and compared these results with those obtained for the secondary metabolites of DEHP. We chose this concentration range in order to take into account the fact that DINCH and DNP could be increasingly used in the composition of medical devices, thus exposure to them is expected to increase in the coming years. It must also be taken into consideration that patients in intensive care units are exposed to several medical devices that may contain these alternative plasticizers (Huygh et al., 2015; Strømmen et al., 2016). Metabolites 7-OH-MMeOP, 7-OH-MMeOCH, 7-cx-MMeOP, 7-cx-MMeOCH do not cause any cytotoxicity up to concentrations of 0.1 mg/mL, just like the corresponding secondary metabolites of DEHP, i.e. 7-OH-MEHP and 5-cx-MEHP. This is also true for 7-oxo-MMeOP, the third secondary metabolite of DNP. However, 7-oxo-MMeOCH, like 5-oxo-MEHP, has been shown to be cytotoxic at 0.1 mg/mL. No cytotoxicity was observed at a concentration below 0.05 mg/mL. The concentrations tested in our study were chosen on the basis of a complete transformation of the plasticizers released after direct contact between a MD and the patient's blood (SCENHIR, 2016; Eckert et al., 2015, 2016). However, the secondary metabolites, derived from the hepatic metabolism of the primary metabolite of the plasticizer (itself derived from an enzymatic hydrolysis of the plasticizer) are present at much lower concentrations in body fluids. Human biomonitoring studies (Schütze et al., 2014; Koch et al., 2007a, 2007b) performed after the introduction of DINCH and DNP on the market show that the concentrations of their secondary metabolites in urinary samples are in the $\mu\text{g/L}$ range (example 0.71 $\mu\text{g/L}$ for 7-OH-MMeOCH, 0.33 $\mu\text{g/L}$ for 7-oxo-MMeOCH, 0.61 $\mu\text{g/L}$ for 7-cx-MMeOCH, 14.9 $\mu\text{g/L}$ for 7-OH-MMeOP, 8.9 $\mu\text{g/L}$ for 7-oxo-MMeOP and 16.4 $\mu\text{g/L}$ for 7-cx-MMeOP), which is about 100–1000 times lower than the concentrations tested. The DEHP secondary metabolites found in the urine of humans exposed for two decades are also in the order of

µg/L (21.0 µg/L for 5-OH-MEHP, 16.7 µg/L for 5-oxo-MEHP, 26.9 µg/L for 5-cx-MEHP) (Wittassek et al., 2007). Therefore, we can consider that these secondary metabolites of DINCH and DINP do not present a risk of cytotoxicity at the doses found in the body. This information, combined with the toxicity data obtained in animals, is reassuring with regard to the use of MDs plasticized with DINCH or DINP for situations where there is no direct contact with the patient's biological fluids (infusers, extension lines, nutrition tubings). In the case of a direct contact between the plasticized PVC in medical device and the patient's blood (extracorporeal circulation in cardiac surgery, dialysis), the risk could be different. In our previous study, we showed the cytotoxicity of primary metabolites of DINP and DINCH at 0.05 mg/mL (Eljezi et al., 2017). During an extracorporeal circulation, the plasticizer released from the MD (extracorporeal circulation line) is hydrolyzed into its glucuroconjugated primary metabolite. However, studies on plasticized DINCH blood bags have shown that this does not affect plasma quality and the amount of DINCH released is less pronounced than that of DEHP (Lagerberg et al., 2015). These results seem to be in agreement with those obtained in rats after i.v. injection or infusion of DINCH for which no apparent systemic effect had been observed up to 300 mg/kg bw/day (David et al., 2015).

It should be noted that these preliminary results attempt to show that the secondary metabolites of DINCH and DINP do not exhibit cytotoxicity according to EN ISO 10-993-5 standards documents. We will consider these different aspects when our biomonitoring study on alternative plasticizers and their corresponding metabolites are complete within the framework of ARMED® and ARMED-NEO projects. We will then select the different compounds for complementary studies.

Declaration of interest

This study is a part of the ARMED® project and received financial support from the French National Agency for the Safety of Medicines and Health Products (ANSM) Grant/award number : AAPR-2012-009.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ijheh.2019.03.005>.

References

- Bernard, L., Cuffe, R., Chagnon, M., Abdoulouhab, F., Décaudin, B., Breyse, C., Kauffmann, S., Cosserant, B., Souweine, B., Sautou, V., 2015. Migration of plasticizers from PVC medical devices: development of an infusion model. *Int. J. Pharm.* 494 (1), 136–145.
- Bhat, V.S., Durham, J.L., Ball, G.L., English, J.C., 2014. Derivation of an oral reference dose (RfD) for the nonphthalate alternative plasticizer 1,2-cyclohexane dicarboxylic acid, di-isononyl ester (DINCH). *J. Toxicol. Environ. Health B Crit. Rev.* 17 (2), 63–94.
- Bourdeaux, D., Yessaad, M., Chennell, P., Larbre, V., Eljezi, T., Bernard, L., Sautou, V., 2016. Analysis of PVC plasticizers in medical devices and infused solutions by GC-MS. *J. Pharm. Biomed. Anal.* 118, 206–213.
- Correia-Sá, L., Schütze, A., Norberto, S., Calhau, C., Domingues, V.F., Koch, H.M., 2017. Exposure of Portuguese children to the novel non-phthalate plasticizer di-(iso-nonyl)-cyclohexane-1,2-dicarboxylate (DINCH). *Environ. Int.* 102, 79–86.
- David, R.M., White, R.D., Larson, M.J., Herman, J.K., Otter, R., 2015. Toxicity of Hexamoll® DINCH® following intravenous administration. *Toxicol. Lett.* 238 (2), 100–109.
- ECHA, 2013. Evaluation of New Scientific Evidence Concerning DINP and DIDP in Relation to Entry 52 of Annex XVII to REACH Regulation (EC) No 1907/2006. Please note: DINP is restricted according Annex XVII of Regulation (EC) No 1907/2006 and can therefore not be used for toys which can be put into the mouth by children. <https://echa.europa.eu/documents/10162/31b4067e-de40-4044-93e8-9c9ff1960715> <https://echa.europa.eu/documents/10162/57096439-2ddd-4f14-b832-85181a09f595>.
- Eckert, E., Müller, J., Göen, T., 2015. Simultaneous determination of polyvinylchloride plasticizers di(2-ethylhexyl) phthalate and tri(2-ethylhexyl) trimellitate and its degradation products in blood by liquid chromatography-tandem mass spectrometry. *J. Chromatogr. A* 1410, 173–180.
- Eckert, E., Münch, F., Göen, T., Purbojo, A., Müller, J., Cesnjevar, R., 2016. Comparative study on the migration of di-2-ethylhexyl phthalate (DEHP) and tri-2-ethylhexyl trimellitate (TOTM) into blood from PVC tubing material of a heart-lung machine. *Chemosphere* 145, 10–16.
- Eljezi, T., Pinta, P., Richard, D., Pinguet, J., Chezal, J.M., Chagnon, M.C., Sautou, V., Grimandi, G., Moreau, E., 2017. In vitro cytotoxic effects of DEHP-alternative plasticizers and their primary metabolites on a L929 cell line. *Chemosphere* 173, 452–459.
- Engel, A., Buhrke, T., Imber, F., Jessel, S., Seidel, A., Völkel, W., Lampen, A., 2017. Agonistic and antagonistic effects of phthalates and their urinary metabolites on the steroid hormone receptors ERα, ERβ, and AR. *Toxicol. Lett.* 277, 54–63.
- Engel, A., Buhrke, T., Kasper, S., Behr, A.C., Braeuning, A., Jessel, S., Seidel, A., Völkel, W., Lampen, A., 2018. The urinary metabolites of DINCH® have an impact on the activities of the human nuclear receptors ERα, ERβ, AR, PPARα and PPARγ. *Toxicol. Lett.* 287, 83–91.
- Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. *Off. J. Eur. Union*.
- Frederiksen, H., Kuiri-Hänninen, T., Main, K.M., Dunkel, L., Sankilampi, U., 2014. A longitudinal study of urinary phthalate excretion in 58 full-term and 67 preterm infants from birth through 14 months. *Environ. Health Perspect.* 122 (9), 998–1005.
- Fromme, H., Schütze, A., Lahrz, T., Kraft, M., Fembacher, L., Siewering, S., Burkardt, R., Dietrich, S., Koch, H.M., Völkel, W., 2016. Non-phthalate plasticizers in German daycare centers and human biomonitoring of DINCH metabolites in children attending the centers (LUPE 3). *Int. J. Hyg Environ. Health* 219 (1), 33–39.
- Giovanoulis, G., Alves, A., Papadopoulou, E., Cousins, A.P., Schütze, A., Koch, H.M., Haug, L.S., Covaci, A., Magnér, J., Voorspoels, S., 2016. Evaluation of exposure to phthalate esters and DINCH in urine and nails from a Norwegian study population. *Environ. Res.* 151, 80–90.
- Giovanoulis, G., Bui, T., Xu, F., Papadopoulou, E., Padilla-Sanchez, J.A., Covaci, A., Haug, L.S., Cousins, A.P., Magnér, J., Cousins, I.T., de Wit, C.A., 2018. Multi-pathway human exposure assessment of phthalate esters and DINCH. *Environ. Int.* 112, 115–126.
- Hauser, R., Calafat, A.M., 2005. Phthalates and human health. *Occup. Environ. Med.* 62 (11), 806–818.
- Huygh, J., Clotman, K., Malarvannan, G., Covaci, A., Schepens, T., Verbrugghe, W., Dirinck, E., Van Gaal, L., Jorens, P.G., 2015. Considerable exposure to the endocrine disrupting chemicals phthalates and bisphenol-A in intensive care unit (ICU) patients. *Environ. Int.* 81, 64–72.
- Jeon, S., Kim, K.T., Choi, K., 2016. Migration of DEHP and DINP into dust from PVC flooring products at different surface temperature. *Sci. Total Environ.* 15 (547), 441–446.
- Johns, L.E., Cooper, G.S., Galizia, A., Meeker, J.D., 2015. Exposure assessment issues in epidemiology studies of phthalates. *Environ. Int.* 85, 27–39.
- Koch, H.M., Angerer, J., 2007. Di-iso-nonylphthalate (DINP) metabolites in human urine after a single oral dose of deuterium-labelled DINP. *Int. J. Hyg Environ. Health* 210 (1), 9–19.
- Koch, H.M., Müller, J., Angerer, J., 2007. Determination of secondary, oxidised di-iso-nonylphthalate (DINP) metabolites in human urine representative for the exposure to commercial DINP plasticizers. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 847 (2), 114–125.
- Koch, H.M., Schütze, A., Pälme, C., Angerer, J., Brüning, T., 2013. Metabolism of the plasticizer and phthalate substitute diisononyl-cyclohexane-1,2-dicarboxylate (DINCH®) in humans after single oral doses. *Arch. Toxicol.* 87 (5), 799–806.
- Koch, H.M., Rütger, M., Schütze, A., Conrad, A., Pälme, C., Apel, P., Brüning, T., Kolossa-Gehring, M., 2017. Phthalate metabolites in 24-h urine samples of the German Environmental Specimen Bank (ESB) from 1988 to 2015 and a comparison with US NHANES data from 1999 to 2012. *Int. J. Hyg Environ. Health* 220 (2 Pt A), 130–141.
- Lagerberg, J.W., Gouwerok, E., Vlaar, R., Go, M., de Korte, D., 2015. In vitro evaluation of the quality of blood products collected and stored in systems completely free of di(2-ethylhexyl)phthalate-plasticized materials. *Transfusion* 55 (3), 522–531.
- Nuti, F., Hildenbrand, S., Chelli, M., Wodarz, R., Papini, A.M., 2005. Synthesis of DEHP metabolites as biomarkers for GC-MS evaluation of phthalates as endocrine disruptors. *Bioorg. Med. Chem.* 13 (10), 3461–3465.
- SCENIHR, February 2008. Scientific Committee on Emerging and Newly-Identified Health Risks) Opinion on the Safety of Medical Devices Containing DEHP-Plasticized PVC or Other Plasticizers on Neonates and Other Groups Possibly at Risk. https://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_014.pdf.
- SCENIHR, February 2016. Scientific Committee on Emerging and Newly-Identified Health Risks) Opinion on the Safety of Medical Devices Containing DEHP-Plasticized PVC or Other Plasticizers on Neonates and Other Groups Possibly at Risk. https://ec.europa.eu/health/sites/health/files/scientific_committees/emerging/docs/scenihr_o_047.pdf.
- Schütze, A., Pälme, C., Angerer, J., Weiss, T., Brüning, T., Koch, H.M., 2012. Quantification of biomarkers of environmental exposure to di(isononyl)cyclohexane-1,2-dicarboxylate (DINCH) in urine via HPLC-MS/MS. *J. Chromatogr. B* 895–896, 123–130.
- Schütze, A., Kolossa-Gehring, M., Apel, P., Brüning, T., Koch, H.M., 2014. Entering markets and bodies: increasing levels of the novel plasticizer Hexamoll® DINCH® in 24 h urine samples from the German Environmental Specimen Bank. *Int. J. Hyg Environ. Health* 217 (2–3), 421–426.
- Schütze, A., Otter, R., Modick, H., Langsch, A., Brüning, T., Koch, H.M., 2017. Additional oxidized and alkyl chain breakdown metabolites of the plasticizer DINCH in urine after oral dosage to human volunteers. *Arch. Toxicol.* 91 (1), 179–188.
- Silva, M.J., Samandar, E., Preau Jr., J.L., Reidy, J.A., Needham, L.L., Calafat, A.M., 2007a. Quantification of 22 phthalate metabolites in human urine. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 860 (1), 106–112.
- Silva, M.J., Reidy, J.A., Kato, K., Preau Jr., J.L., Needham, L.L., Calafat, A.M., 2007b. Assessment of human exposure to di-isodecyl phthalate using oxidative metabolites

- as biomarkers. *Biomarkers* 12 (2), 133–144.
- Silva, M.J., Jia, T., Samandar, E., Preau Jr., J.L., Calafat, A.M., 2013. Environmental exposure to the plasticizer 1,2-cyclohexane dicarboxylic acid, diisononyl ester (DINCH) in U.S. adults (2000–2012). *Environ. Res.* 126, 159–163.
- Strømmen, K., Lyche, J.L., Blakstad, E.W., Moltu, S.J., Veierød, M.B., Almaas, A.N., Sakhi, A.K., Thomsen, C., Nakstad, B., Brække, K., Rønnestad, A.E., Drevon, C.A., Iversen, P.O., 2016. Increased levels of phthalates in very low birth weight infants with septicemia and bronchopulmonary dysplasia. *Environ. Int.* 89–90, 228–234.
- Wittassek, M., Wiesmüller, G.A., Koch, H.M., Eckard, R., Dobler, L., Müller, J., Angerer, J., Schlüter, C., 2007. Internal phthalate exposure over the last two decades—a retrospective human biomonitoring study. *Int. J. Hyg Environ. Health* 210 (3–4), 319–333.
- Zeman, F.A., Boudet, C., Tack, K., Floch-Barneaud, A., Brochot, C., Péry, A.R., Oleko, A., Vandentorren, S., 2013. Exposure assessment of phthalates in French pregnant women: results of the ELFE pilot study. *Int. J. Hyg Environ. Health* 216 (3), 271–279.
- Zhang, S., Ma, J., Fu, Z., Zhang, Z., Cao, J., Huang, L., Li, W., Xu, P., Cao, X., 2016. Promotion of breast cancer cells MDA-MB-231 invasion by di(2-ethylhexyl)phthalate through matrix metalloproteinase-2/-9 overexpression. *Environ. Sci. Pollut. Res. Int.* 23 (10), 9742–9749.